Company Overview and News

29
Chesapeake Stock Could Be a Good Pick for Some Investors

1h investorplace
Chesapeake Energy (NYSE:CHK) has been on a roller coaster ride for the past 12 months. The ups and downs of CHK stock price have been driven by fluctuations in fuel prices as well as the company’s struggle to pay down its massive debt load.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

29
Chesapeake Energy stock slips to endanger 5-day win streak after analyst downgrade

2h marketwatch
Chesapeake Energy Corp. CHK, -0.11% was downgraded by SunTrust RH analyst Neal Dingmann, who said the oil and gas producer's turnaround could take longer than expected. The stock slipped 0.3% morning trade, after soaring 17% amid a five-session win streak through Monday. Dingmann cut his rating to hold, after being at buy for at least the past three years, and lowered his price target to $5 from $6.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

173
The Zacks Analyst Blog Highlights: Cabot Oil, Chesapeake, Comstock, Southwestern and SilverBow

3h zacks
Chicago, IL –September 25, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cabot Oil & Gas Corp. (COG - Free Report) , Chesapeake Energy Corp. (CHK - Free Report) , Comstock Resources, Inc. (CRK - Free Report) , Southwestern Energy Co.
CKRGZ CQP LNG CHKVP RAD CRK COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TITN

69
Top Analyst Upgrades and Downgrades: Barrick Gold, Blackstone, Chesapeake Energy, Dollar Tree, Intel, Qualcomm, Sirius XM, TI, Vale and More

3h 247wallst
Stocks have hit all-time highs, and Monday’s losses were followed with what looked to be a positive open on Tuesday for the major equity indexes. The markets are dealing with trade tariffs and with the Federal Reserve meeting this week. Many investors also have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how to position their investments for the rest of 2018 and as 2019 approaches.
CHKVP AVP CHKDH CHKVZ CENT CLH ABT CNI CHKDG DLTR SIRI CHKDJ HUN CHKDP MS INTC ABX ABT CKRGZ ABX BX MCHP ON CADE CHKWZ NITE WEN HP BJ CZR CHK CHK.WI TRI QCOM TS CLX

40
Natural Gas Posts Sharp Weekly Gain on Hefty Storage Deficit

19h zacks
The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. Despite the headline miss, a hefty storage deficit ahead of the upcoming winter pointed to tightening fundamentals and spurred the fuel’s price, which gained about 7.6% for the week.
ECR CKRGZ CQP LNG CHKVP CRK RDN COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR

92
The Risks Significantly Outweigh the Rewards of Owning Tesla Stock

2018-09-23 investorplace
The chaos at Tesla (NASDAQ:TSLA) continues. Tesla stock finds itself stuck in a trading range as production glitches, management turnover, falling bond prices, and investigations hamper the equity.Still, the stock price remains at a high level despite the turmoil.
CKRGZ CHKVP CHKDH CHKVZ TLRY CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TSLA GM

29
Chesapeake Energy Stock Remains High-Risk, High-Reward

2018-09-19 investorplace
Over the past year or so, I’ve recommended Chesapeake Energy (NYSE:CHK) as a high-risk, high-reward play. I even briefly owned Chesapeake Energy stock last year. Whether those calls were correct comes down mostly to timing: CHK stock continues to trade sideways, dipping below $3 earlier this year and climbing above $5 in July before yet another pullback to about $4.
CKRGZ CHKVP COG FTSI CHKDH CHKVZ AR CHKDG CHKWZ CHKDJ EQT CHKDP CHK CHK.WI

34
Blue Ridge Mountain Resources Announces Key Executive Management Appointment

2018-09-19 globenewswire
IRVING, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Blue Ridge Mountain Resources, Inc. (OTCPK: BRMR) (“Blue Ridge” or the “Company”) today is pleased to announce the appointment of Michael Hodges to Senior Vice President of Finance. Michael’s first day with the Company will be September 19, 2018. Effective upon the successful completion of the Company’s proposed merger with Eclipse Resources Corporation (NYSE: ECR) (“Eclipse”), Michael will assume the role of Executive Vice President and Chief Financial Officer of Eclipse from Matthew DeNezza, who is currently serving in such capacity with Eclipse.
ECR CKRGZ BRMR CHKVP SDRPQ CHKDH CHKVZ SD CHKDG CHKWZ SDOCQ CHKDJ REXX CHKDP RXNRP CHK.WI CHK REXXQ SDRXP SDRXQ

29
Chesapeake Energy's Sweet Spots

2018-09-18 seekingalpha
Investors know that for a while now Chesapeake has struggled under debt and high capex requirements.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

33
GUSH Is At Buy Levels Of A Lifetime

2018-09-17 seekingalpha - 2
The ETF is a leveraged play on the recovery in oil & gas, which is currently underway.
CRC CKRGZ APA CHKVP CTLR DVN GUSH CHKDH CHKVZ EOG CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK CLR

29
Why I Doubled Down Aggressively On Chesapeake Energy Corp.

2018-09-17 seekingalpha
Chesapeake Energy Corp. is a much leaner company compared to just 2, 3 years ago, and has repaid more than 50 percent of debt since 2012.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

40
Natural Gas Supply Deficit Grows but Faces Florence Threat

2018-09-17 zacks
The U.S. Energy Department's weekly inventory release showed a marginally smaller-than-expected increase in natural gas supplies. Despite the headline beat and a growing storage deficit, strong production and the expected power loss from Hurricane Florence weighed on the fuel’s price, which ended flat over the week.
ECR CKRGZ CQP LNG CHKVP CRK COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR

29
Chesapeake Energy: The Coming Rally Will Not Disappoint

2018-09-17 seekingalpha
Oil prices should resume their climb after the November election and push the stock price up with that rally.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ

33
Meet the Shalennials: CEOs under 40 making millions in Texas Oil

2018-09-16 nzherald.co.nz
John Sellers and Cody Campbell are holding court one hot August evening in the corner of an oil-themed dive bar in Midland, Texas. After flying in on their private jet, they're shaking hands, cracking jokes and talking deals with aspiring oilmen, contractors and land traders, almost all in their early 30s. A life-size, stuffed grizzly bear stands by a wall wearing a baseball cap embossed with: "Make Oil & Gas Great Again.
CKRGZ XOM CHKVP DVN PE CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK MRO TPL

35
The Millennials Making Millions In Texas Oil

2018-09-15 oilprice - 1
MINING.com is a web-based global mining publication focusing on news and commentary about mining and mineral exploration. The site is a one-stop-shop for mining industry…
CKRGZ XOM CHKVP DVN PE CHKDH CHKVZ APO CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK MRO TPL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...